Growth continued in Q2, profitability better but more to be achieved
31/07/20 -"AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a ..."
Pages
77
Language
English
Published on
31/07/20
You may also be interested by these reports :
10/08/20
Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled ...
10/08/20
Bayer (Buy, Germany) has managed to exhaust its shareholders and analysts alike as it navigated the stupidity of acquiring Monsanto back in 2017. As ...
07/08/20
After an impressive Q1, driven by COVID-19-induced stocking, growth fizzled out in Q2. GLP-1 offerings continue to do well, but headwinds in insulins ...
07/08/20
Despite the integration of BCN Pharma, Faes’ Q2 top-line came under pressure primarily due to the decline in sales of Bilastine (due to the reduction ...